Johnson & Johnson (J&J) of the United States announced on the 25th (local time) that antibody levels were found to significantly increase when receiving a booster shot (boost shot) developed by Janssen, a pharmaceutical subsidiary.
J&J announced that the initial clinical trial results showed that when participants received the second vaccine six months after receiving the Janssen vaccine, their antibody levels were 9 times higher compared to four weeks after the first dose.
For the Janssen vaccine, which is administered with only one dose, the second dose is a booster shot.
The New York Times (NYT) reported that J&J plans to submit the clinical trial data to the US Food and Drug Administration (FDA).
The FDA is reviewing the results of previously submitted vaccine booster shots from Pfizer-BioNtech and Moderna.
The Janssen vaccine was not included in the booster shot vaccination plan recently announced by the Joe Biden administration. are doing
J&J also found that after six months of follow-up of 17 of last year's vaccine trial participants, there was little change in antibody levels.
This is a different pattern from the Pfizer-BioNtech and Moderna vaccines, which show a high level of protection in the beginning and then drop in antibody levels after several months, the New York Times noted.
According to data submitted for emergency use approval by the FDA in February, the initial preventive effect of the Janssen vaccine was 72%.
Details such as the extent to which the recently prevalent delta mutation affects the preventive effectiveness of the Janssen vaccine were not included in the announcement.
In addition, despite reports that the preventive effect of the Janssen vaccine lasts for a long time, the question of why a booster shot is needed is raised, CNBC said.
(Photo = Yonhap News)